Comprehensive Genomic Profiling

The AJMC® Comprehensive Genomic Profiling compendium is a comprehensive resource for clinical news and expert insights for the next-generation sequencing approach to assess genes for the purpose of therapy guidance.

Latest News
December 17th 2022

ICYMI: Highlights From the 2022 American Academy of Dermatology Meeting

July 19th 2022

WGS Feasible, Valuable in Metastatic Cancer Management

July 16th 2022

Survey Provides Insight Into Patient Experiences Receiving Comprehensive Tumor Genomic Profiling Results

July 7th 2022

Method of Tissue Acquisition May Determine Success of Gene Sequencing in Lung Cancer

July 1st 2022

FOENIX Update: A New Era in Cholangiocarcinoma Precision Medicine

Advancing Precision Medicine Through Comprehensive Genomic Profiling (CGP)

Payer and clinician insight regarding the integration of comprehensive genomic profiling into routine clinical practice to help oncologists make more informed treatment decisions for patients with cancer.

Bruce Feinberg.
Video Interviews
View All
November 12th 2022

Dr Joseph Alvarnas: Cancer Care Equity Act Meets the Needs of Patients With Advanced Disease

June 30th 2022

Dr Elli Papaemmanuil Discusses Molecular Profiling of MDS, Use of Precision Medicine

June 22nd 2022

Dr Hatem Soliman Explains How the DNA Damage Repair Pathway Affects Cancer Progression

June 18th 2022

Dr Patricia Deverka Discusses Potential Collaborations for Real-world MCED Data Collection

June 10th 2022

Dr Patricia Deverka Addresses Potential Disparities in Multicancer Early Detection Tests

June 3rd 2022

NPC's Michael Ciarametaro Lists 3 Ways the Gene Therapy Market Addresses Value-Based Contract Concerns

May 20th 2022

Dr Patricia Deverka on Determining Value of Multicancer Detection Tests

May 13th 2022

Dr Patricia Deverka Explains Next Steps Toward Medicare Coverage of Multicancer Early Detection Tests

May 5th 2022

Dr Sneha Sharma Discusses the Growing Roles of Biomarker Testing, Biosimilars

April 29th 2022

Dr Patricia Deverka Discusses Access, Research for Multicancer Early Detection Tests

More News

dna in a test tube
June 28th 2022

Lack of CGP Testing May Result in Missed Therapy Options in NSCLC

Skylar Jeremias
A real-world analysis found that comprehensive genomic profiling (CGP) in patients with non–small cell lung cancer (NSCLC) increases their therapy options patients and CGP testing needs to be utilized more.
Athletes running.
June 17th 2022

ESC Genetic Testing Recommendations Address Sudden Cardiac Death Risk in Athletes

Matthew Gavidia
Recommendations discuss appropriate use and diagnostic, prognostic, and therapeutic implications of cardiac genetic testing, including guidance on impact of exercise.
dna in a vial
June 11th 2022

AACR Posters Demonstrate CGP for Biomarker Detection and Multiomics Profiling

Skylar Jeremias
Posters from the American Association of Cancer Research (AACR) Annual Meeting demonstrated the use of genomic profiling and sequencing can detect immunotherapy biomarkers and predict clinical outcomes in patients with cancer.
Martin Dawes.
June 2nd 2022

Contributor: The Case for Education and Clinical Decision Support With Pharmacogenetics

Martin Dawes, MBBS, MD, FRCGP, CCFP
Prescribing is a complex process with multiple factors to consider on top of the 3 primary questions about effectiveness, harm, and cost. Pharmacogenetics has put this complexity under the spotlight and prompted educational programs and the development of new clinical decision support systems.
targets
May 24th 2022

As Number of Targeted Therapies Increases, Challenges With Precision Medicine Are Not Going Away

Laura Joszt, MA
There are an increasing number of targeted therapies in oncology, but challenges around biomarker testing and treatment selection remain.
Bill Kerr, MD.
May 17th 2022

Contributor: The Convergence of Value-Based Care and Lab Testing Growth

Bill Kerr, MD
Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.
DNA strands
May 11th 2022

Assessing Cost Savings, Waste Reduction From Pharmacogenomics and Precision Medicine

Gianna Melillo
David Skomo, and Nick Page, PharmD, of WellDyne offered their perspectives on recent developments in precision medicine at the 2022 Asembia Specialty Pharmacy Summit.
microscope.
May 7th 2022

Next-Generation Sequencing Finds Different Molecular Profiles of Pediatric, Adult Sarcomas

Matthew Gavidia
Next-generation sequencing identified different molecular profiles of pediatric and adult sarcomas among Chinese patients.
blood stream with red blood cells in view
April 24th 2022

Contributor: Top 3 Future Therapies to Drive Hemophilia Treatment Market Growth

Ashwin Avhad
The trends in the hemophilia treatment market are gaining momentum with increasing incidences of hemophilia A and B and staggering need for their treatments, including gene, anti-tissue factor pathway inhibitor, and factor replacement therapies.
Michael Ciarametaro, MBA
April 22nd 2022

NPC's Michael Ciarametaro on How Clinics Can Surmount Gene Therapy Data Collection Barriers

Skylar Jeremias
Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.
Health care technology.
April 20th 2022

Spotlighting Health-, Cost-Related Benefits of Genomic Testing and How Employers Can Drive Adoption

Matthew Gavidia
Key opinion leaders addressed cost, accessibility, and other barriers limiting use of comprehensive genomic profiling (CGP), and how employers can help drive preventive care and precision medicine through CGP.
woman in a lab using a microscope
April 15th 2022

Expert: Better Harmony Is Needed to Prevent Compromised Specimens During CGP Testing

Skylar Jeremias
Despite technological advancements, there are still many factors that can cause specimens for comprehensive genomic profiling (CGP) testing to become compromised, potentially leading to inaccurate prognostic results, according to a recent webinar.
Genomic testing.
April 8th 2022

Genomic Profiling Utility for Targeted Therapy Selection Shown in Advanced GI Cancers

Matthew Gavidia
The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.
Jorge Plutzky, MD
April 6th 2022

Dr Jorge Plutzky: New Advances in Science, Medicine Need to Move Into Practice Quicker

The acceleration of science and medicine is exciting, but these new advances are not always moving into practice, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School.
Edmondo Robinson, MD, MBA, MS, FACP, Moffitt Cancer Center
March 30th 2022

Dr Edmondo Robinson Highlights the Importance of a Complete Patient View When Delivering Care

Laura Joszt, MA
Everything from the genomic data for the cancer to the zip code of a patient matters when delivery care, said Edmondo Robinson, MD, MBA, MS, FACP, senior vice president and chief digital officer at Moffitt Cancer Center.
close up image of DNA
March 28th 2022

ASCO GU 2022: Comparing Tumor Genomic Landscape Across Age, Disease Demographics

Posters from the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2022 look at how the tumor genomic landscape differs based on age and type of urothelial carcinoma.
What we're reading stock photo.
March 22nd 2022

What We're Reading: ACA Enrollment Expands; Seizure Disorder Treatment Approved; Biomarker Testing Program Launch

AJMC Staff
The special enrollment period for Affordable Care Act (ACA) coverage has opened to low-income Americans; the FDA approves the first drug for a rare genetic epilepsy disorder; the National Institutes of Health to launch biomarker testing program for pediatric tumors.
DNA on a computer screen
March 21st 2022

ASCO Publishes Recommendations for Genomic Testing in Metastatic Cancer

AJMC Staff
A provisional clinical opinion from the American Society of Clinical Oncology (ASCO) recommends that patients with advanced cancer with specific genomic alterations undergo genomic sequencing.
FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLC
March 19th 2022

FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLC

AJMC Staff
FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.
mother rubbing her daughters head as she holds a teddy bear in a hospital bed
March 16th 2022

Tumor Genome Sequencing Enables Children With Cancer to Receive Targeted Therapies

Skylar Jeremias
Genome sequencing of tumors from children and adolescents with recurrent or refractory cancer led to over 100 patients receiving targeted therapies.
Ron Do, PhD, and Iain Forrest, MD-PhD candidate
March 14th 2022

Mount Sinai Researchers Discuss Milestones in Understanding Genetic Variants

Hayden E. Klein
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Ron Do, PhD, and Iain Forrest, MD-PhD candidate
March 12th 2022

Mount Sinai Researchers Explain Implications of Genetic Testing for Providers

Hayden E. Klein
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Ron Do, PhD, and Iain Forrest, MD-PhD candidate
March 4th 2022

Mount Sinai Researchers Explain Biobanks Used in Clinical Variants Study

Hayden E. Klein
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
magnifying glass over a model of DNA
March 2nd 2022

Thermo Fisher Scientific Stages Open Call for Grant Proposals Supporting Oncology Molecular Profiling

Skylar Jeremias
Thermo Fisher Scientific will begin accepting submissions for grant proposals focusing on molecular profiling in cancer spaces, where applicants could receive up to $200,000 in funding.
Ron Do, PhD, and Iain Forrest, MD-PhD candidate
February 26th 2022

Mount Sinai Researchers Discuss Findings on Risk of Pathogenic, Loss-of-Function Clinical Variants

Hayden E. Klein
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss the results of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
health care cost.
February 26th 2022

How Employers Can Achieve High-Value, Cost-Effective Oncology Care Through Genomic Profiling

Matthew Gavidia
A webinar by the National Cancer Treatment Alliance discussed current use and diagnostic/therapeutic benefits of comprehensive genomic profiling in oncology, as well as recommendations for employers and benefit consultants considering biomarker testing.
Ron Do, PhD, and Iain Forrest, MD-PhD candidate
February 19th 2022

Mount Sinai Researchers on Importance of Understanding Genetic Variants and Disease Risk

Hayden E. Klein
Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
a model of DNA surrounded by data
February 15th 2022

FDA Grants Breakthrough Device Designation to Foundation Medicine’s ctDNA Tracker

Skylar Jeremias
Foundation Medicine’s circulating tumor DNA (ctDNA) detection and monitoring assay, FoundationOne Tracker, was granted a Breakthrough Device Designation from the FDA, streamlining the approval and review processes to give patients and providers earlier access to the device.
DNA.
February 15th 2022

Tumor Mutational Burden May Help Predict Immunotherapy Response in Metastatic NSCLC

Matthew Gavidia
Response to immunotherapy and survival outcomes were found to be significantly associated with tumor mutational burden in patients with stage IV non-small cell lung cancer.
Megan Olsen, MPH
February 10th 2022

Avalere Analyst on How Payers Are Handling Cell and Gene Therapy Cost Concerns

Skylar Jeremias
Megan Olsen, MPH, principal at Avalere, explains how payers are attempting to get around cost concerns associated with expensive cell and gene therapies.
1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo